Abstract: The invention features a method for evaluating PKC activity in vascular tissues. The invention also features methods for diagnosing cardiovascular and diabetes related disorders, and for identifying and evaluating treatments for cardiovascular or diabetes related disorders. Methods for identifying and evaluating treatments for aging are also included. The methods include measuring PKC activity in monocytes as a surrogate for PKC activity in other tissues.

Abstract: Methods of treating a subject having an insulin-related disorder, e.g., diabetes. The methods include reducing the amount of p85 PI3K regulatory subunit isoform in a cell of the subject.

Abstract: Featured are methods of modulating endothelial NOS (eNOS) expression, e.g., insulin-stimulated eNOS expression, by modulating PKC&bgr;. The methods are useful in the treatment of insulin-related disorders, e.g., hypertension.

Abstract: Featured are methods of modulating angiogenesis, e.g., by modulating PKC delta. The methods are useful in the treatment of disorders characterized by aberrant and/or increased blood vessel formation and/or increased permeability. The methods are also useful for treatment a disorder characterized by abnormal, inadequate or unstable blood vessel formation or increased permeability. Also featured are diagnostic and screening methods.

Abstract: The invention features a method of identifying, evaluating or making a compound or agent, e.g., a candidate compound or agent, for treatment of a disorder characterized by insulin resistance. The method includes evaluating the ability of a compound or agent to bind IKK-&bgr; or modulate IKK-&bgr; activity, to thereby identify a compound or agent for the treatment of a disorder characterized by insulin resistance. The invention also features compounds for treating insulin resistance identified by such methods, and methods of treating a subject having a disorder characterized by insulin resistance by administering such agents.

Abstract: The invention features a method of identifying, evaluating or making a compound or agent, e.g., a candidate compound or agent, for treatment of a disorder characterized by insulin resistance. The method includes evaluating the ability of a compound or agent to bind IKK-&bgr; or modulate IKK-&bgr; activity, to thereby identify a compound or agent for the treatment of a disorder characterized by insulin resistance. The invention also features compounds for treating insulin resistance identified by such methods, and methods of treating a subject having a disorder characterized by insulin resistance by administering such agents.

Abstract: The invention features a method of identifying, evaluating or making a compound or agent, e.g., a candidate compound or agent, for treatment of a disorder characterized by insulin resistance. The method includes evaluating the ability of a compound or agent to interact with, e.g., bind, IKK-&bgr;, to thereby identify a compound or agent for the treatment of a disorder characterized by insulin resistance. The invention also features compounds for treating insulin resistance identified by such methods, and methods of treating a subject having a disorder characterized by insulin resistance by administering such agents.

Abstract: The invention is directed to immunologically privileged cells, e.g., autologous, allogeneic, and xenogeneic intermediate lobe pituitary cells, for delivering polypeptides, e.g., insulin, to a subject, and to methods of using the same.

Abstract: Purified DNA including a sequence encoding Diabetogene rad.

Abstract: The invention provides methods of determining whether a subject is at risk for a disorder characterized by an intermediate GAA repeat length polymorphism in the frataxin gene.

Abstract: The invention relates to novel mutant SH2 domain containing protein tyrosine phosphatases wherein the phosphatase is partially or constitutively active; and whose ability to regulate biological processes are different from the wildtype protein tyrosine phosphatases. The invention also relates to methods of use of the novel mutants, for example, in in vitro assays to screen for binding partners and inhibitors of protein tyrosine phosphatases and in the treatment of protein tyrosine phosphatase mediated diseases or conditions.

Abstract: A method for inhibiting VEGF stimulated endothelial cell growth, such as associated with macular degeneration, and VEGF stimulated capillary permeability, such as associated with macular edema are disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bis -(3,3'-indoly 1)]-1(H)-pyrrole-2,5-dionehydrochloridesalt.

Abstract: An image acquisition unit provides true color high resolution digital images of the retina of the eye to a computer network (14, 16, 18) which interfaces with a central record library and displays the images at a remote work station (20A and 20B) for diagnostic examination. The computer network (14, 16, 18) is also interfaced with a unit for entering medical history information, and the diagnostic data, stereo images and medical records are linked in a relational database allowing all text and image records of the patient to reside on a work station/display (20A and 20B) for review or consultation. A telecommunications link (22) interconnects the computer network and image examination stations with the image acquisition station where the patient is actually examined, so that stereo fundus images may be made available through the computer without degradation for viewing on the examination displays remotely from the room, building, or city where the images are acquired from the patient.

Abstract: A 69 kD protein, designated PM-1, is expressed in human pancreatic islet cells and a human insulinoma. The amino acid sequence of the protein has been determined. Autoantibodies to the PM-1 protein have been found in sera of prediabetic patients. Natural, synthetic or recombinant forms of the PM-1 protein can be used in immunochemical assays to detect anti-PM-1-autoantibodies and to identify patients at risk of developing diabetes.

Abstract: Purified DNA including a sequence encoding Diabetogene rad.

Abstract: A substantially pure nucleic acid comprising a sequence encoding an IRS-2 polypeptide, a substantially pure preparation of an IRS-2 polypeptide, and related methods.

Abstract: A method for promoting eating, the gain of weight or maintenance of weight in a subject. The method includes administering to the subject an effective amount of melanocyte concentrating hormone (MCH) or agonist thereof.

Abstract: A method evaluating the tumor promoter agonist or antagonist activity or the PKC activator or inhibitor activity of a compound. The method includes supplying a yeast cell expressing a PKC , contacting the yeast cell with a compound to be evaluated; and determining the value of a parameter related to tumor promoter agonist or antagonist or PKC activator or inhibitor activity in the cell, the effect of compound on the value of the parameter being indicative of the tumor promtoer or PKC activator or inhibitor activity of the compound.

Abstract: A substantially pure nucleic acid comprising a sequence encoding a pp60.sup.PIK peptide and methods of using nucleic acid encoding pp60.sup.PIK to make pp60.sup.PIK polypeptide.

Abstract: A purified protein that is identified herein as insulin receptor substrate 1 (IRS-1) is disclosed, as well as a method of purifying IRS-1 and a recombinant nucleic acid encoding it.